{
    "organizations": [],
    "uuid": "7405bf2995de2c81a38d069ffbc86dcaebfb27cb",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ablynx-nv-ablynx-commences-dosing/brief-ablynx-nv-ablynx-commences-dosing-in-its-phase-ii-study-of-alx-0171-in-hospitalised-japanese-infants-with-a-rsv-infection-idUSFWN1QK00L",
    "ord_in_thread": 0,
    "title": "BRIEF-Ablynx NV ‍Ablynx Commences Dosing In Its Phase II Study Of Alx-0171 In Hospitalised Japanese Infants With A Rsv Infection​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 2 (Reuters) - Ablynx Nv:\n* ‍ABLYNX COMMENCES DOSING IN ITS PHASE II STUDY OF ALX-0171 IN HOSPITALISED JAPANESE INFANTS WITH A RSV INFECTION​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-02T14:23:00.000+02:00",
    "crawled": "2018-03-03T17:23:29.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "ablynx",
        "nv",
        "commences",
        "dosing",
        "phase",
        "ii",
        "study",
        "hospitalised",
        "japanese",
        "infant",
        "rsv",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}